{"filing":{"accession_number":"0001840199-26-000108","cik":"0001840199","ticker":"WALDW","company_name":"Waldencast plc","form":"6-K","filing_date":"2026-09-28","report_date":"2026-06-30","primary_document":"a1wald6-k_earningsreleasex.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840199/000184019926000108/a1wald6-k_earningsreleasex.htm"},"events":[{"id":35474,"run_id":32675,"accession_number":"0001840199-26-000108","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This exhibit is a press release announcing Waldencast plc's first half 2026 financial results, dated September 28, 2026. It discloses net revenue from continuing operations of $26.1 million (down 57.1% YoY), net loss from continuing operations of $94.9 million (up 96.5% YoY), and a $52.3 million goodwill impairment charge against Milk Makeup. The release includes detailed financial highlights, a shareholder letter, and forward-looking strategy. While the exhibit also discusses the completed sale of Obagi Medical (a material M\u0026A event), the primary disclosure vehicle and structure is a financial results announcement for the six-month period ended June 30, 2026, making this an earnings_release rather than a periodic report.","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-09-28","form":"6-K","submitted_at":null,"items":[{"id":39535,"accession_number":"0001840199-26-000108","item_number":"EX-99.1","item_title":"a1wald_earningsxex991xq220.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Waldencast plc's first half 2026 financial results, dated September 28, 2026. It discloses net revenue from continuing operations of $26.1 million (down 57.1% YoY), net loss from continuing operations of $94.9 million (up 96.5% YoY), and a $52.3 million goodwill impairment charge against Milk Makeup. The release includes detailed financial highlights, a shareholder letter, and forward-looking strategy. While the exhibit also discusses the completed sale of Obagi Medical (a material M\u0026A event), the primary disclosure vehicle and structure is a financial results announcement for the six-month period ended June 30, 2026, making this an earnings_release rather than a periodic report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:32:10.264276+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39535,"accession_number":"0001840199-26-000108","item_number":"EX-99.1","item_title":"a1wald_earningsxex991xq220.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Waldencast plc's first half 2026 financial results, dated September 28, 2026. It discloses net revenue from continuing operations of $26.1 million (down 57.1% YoY), net loss from continuing operations of $94.9 million (up 96.5% YoY), and a $52.3 million goodwill impairment charge against Milk Makeup. The release includes detailed financial highlights, a shareholder letter, and forward-looking strategy. While the exhibit also discusses the completed sale of Obagi Medical (a material M\u0026A event), the primary disclosure vehicle and structure is a financial results announcement for the six-month period ended June 30, 2026, making this an earnings_release rather than a periodic report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:32:10.264276+00:00","company_name":"Waldencast plc","ticker":"WALDW","filing_date":"2026-09-28"}]}